Involvement of nuclear factor-κB in a murine model for the acute form of autoimmune-like toxic oil syndrome

Toxicology and Applied Pharmacology

Volumn 157, Issue 3, 1999, Pages 213-221

  Bell, Susanne A ^a   Page, Sharon ^b   Baumgartner, Bastian ^b   Berking, Carola ^a   Haas, Monika ^b   Eisele, Tamara ^b   Neumeier, Dieter ^b   Brand, Korbinian ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Autoimmune disease; Chemically induced; Murine model; NF B; Toxic oil syndrome

Indexed keywords

ANILINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; OLEIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; APATHY; ARTICLE; AUTOIMMUNE DISEASE; BREATHING DISORDER; CACHEXIA; CONTROLLED STUDY; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC OIL SYNDROME; WASTING SYNDROME; WEIGHT REDUCTION;

EID: 0033564501     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8684     Document Type: Article

References (52)

1. Aderka D., Wysenbeek A., Engelmann H., Cope A. P., Brennan F., Molad Y., Hornik V., Levo Y., Maini R. N., Feldmann M., Wallach D. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 36:1993;1111-1117.
2. Al-Janadi M., Al-Balla S., Al-Dalaan A., Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J. Clin. Immunol. 13:1993;58-63.
3. Alonso-Ruiz A., Zea M. A., Salazar V. J., Rocamora R. A., Beltran G. J. Toxic oil syndrome: A syndrome with features overlapping those of various forms of scleroderma. Semin. Arthritis Rheum. 15:1986;200-212.
4. Alonso-Ruiz A., Calabozo M., Perez R. F., Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine (Baltimore). 72:1993;285-295.
5. Arnaiz-Villena A., Martinez-Laso J., Corell A., Allende L., Rosal M., Gomez-Reino J. J., Vicario J. L. Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome. Eur. J. Immunogenet. 23:1996;211-219.
6. Arsura M., Wu M., Sonenshein G. E. TGF beta inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: Transcriptional activation of I kappa B alpha. Immunity. 5:1996;31-40.
7. Baeuerle P. A., Henkel T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
8. Baeuerle P. A., Baltimore D. NF-κB: Ten years after. Cell. 87:1996;13-20.
9. Baldwin A. S. The NF-κB and IκB proteins: New discoveries and insights. Annu. Rev. Immunol. 14:1996;649-681.
10. Barnes P. J., Karin M. Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1997;1066-1071.
11. Bell S. A., Hobbs M. V., Rubin R. L. Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome. J. Immunol. 148:1992a;3369-3376.
12. Bell S. A., Brand K., Meurer M. Das Toxic Oil Syndrome - Beispiel einer exogen induzierten Autoimmunerkrankung. The toxic oil syndrome - an example of an exogenously induced autoimmune disease. Hautarzt. 43:1992b;339-343.
13. Bell S. A. The toxic oil syndrome: An example of an exogenously induced autoimmune reaction. Mol. Biol. Rep. 23:1997;261-263.
14. Berking C., Hobbs M. V., Chatelain R., Meurer M., Bell S. A. Strain-dependent cytokine profile and susceptibility to oleic acid anilide in a murine model of the toxic oil syndrome. Toxicol. Appl. Pharmacol. 148:1998;222-228.
15. Boswell J. M., Yui M. A., Burt D. W., Kelley V. E. Increased tumor necrosis factor and IL-1β gene expression in the kidneys of mice with lupus nephritis. J. Immunol. 141:1988;3050-3054.
16. Brand K., Mackman N., Curtiss L. K. Interferon-γ inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J. Clin. Invest. 91:1993;2031-2039.
17. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., Page M., Kaltschmidt C., Baeuerle P. A., Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J. Clin. Invest. 97:1996;1715-1722.
18. Brand K., Page S., Walli A. K., Neumeier D., Baeuerle P. A. Role of nuclear factor κB in atherogenesis. Exp. Physiol. 82:1997a;297-304.
19. Brand K., Eisele T., Kreusel U., Page M., Page S., Haas M., Gerling A., Kaltschmidt C., Neumann F.-J., Mackman N., Baeuerle P. A., Walli A. K., Neumeier D. Dysregulation of monocytic nuclear factor-κB by oxidized low-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 17:1997b;1901-1909.
20. Burkhardt H., Kalden J. R. Xenobiotic immunosuppressive agents: Therapeutic effects in animal models of autoimmune disease. Rheumatol. Int. 17:1997;85-90.
21. Diaschenko G. W., Yurawecz M. P., Puma B. J., Dreifuss P. A., Chen J. T., Egry I., Carver R. Identification of fatty acid anilides in adulterated Spanish cooking oils. Bull. Environ. Contam. Toxicol. 29:1982;228-234.
22. Ford W. L. The preparation and labelling of lymphocytes. Handbook of Experimental Immunology. 1978;Blackwell Scientific Publications. p. 23.1.
23. Freixa R., Casas J., Messeguer A., Roselló J., Gelpi E. Byproduct identification in the carbodiimide-assisted synthesis of fatty acid anilides related to spanish toxic oil syndrome. J. Agric. Food. Chem. 34:1986;738-742.
24. Glowinski I. B., Weber W. W. Genetic regulation of aromatic amine N-acetylation in inbred mice. J. Biol. Chem. 257:1982;1424-1430.
25. Goldman M., Druet P., Gleichmann E. Th2 cells in systemic autoimmunity: Insights from allogeneic diseases and chemically-induced autoimmunity. Immunol. Today. 12:1991;223-227.
26. Grandjean, P, Tarkowski, S, Faro, V, Rigau-Perez, J. G, Koch, G. K, Serrano-Rios, M, and, Tabuenca, J. M. 1983, Toxic oil syndrome. Mass food poisoning in Spain. Report on a WHO Meeting, Madrid, 1983.
27. Griem P., Wulferink M., Sachs B., González J. B., Gleichmann E. Allergic and autoimmune reactions to xenobiotics: How do they arise? Immunol. Today. 19:1998;133-141.
28. Haas M., Page S., Page M., Neumann F.-J., Marx N., Adam M., Ziegler-Heitbrock H. W. L., Neumeier D., Brand K. Effect of proteasome inhibitors on monocytic IκB-α and -β depletion, NF-κB activation and cytokine production. J. Leuk. Biol. 63:1998;395-404.
29. Hertzman P. A. The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels. Adv. Med. Biol. 398:1996;339-342.
30. Hobbs M. V., Weigle W. O., Noonan D. J., Torbett B. E., McEvilly R. J., Koch R. J., Cardenas G. J., Ernst D. N. Patterns of cytokine gene expression by CD4+ T cells from young and old mice. J. Immunol. 150:1993;3602-3614.
31. Hobbs M. V., Weigle W. O., Ernst D. N. Interleukin-10 production by splenic CD4+ cells and cell subsets from young and old mice. Cell. Immunol. 154:1994;264-272.
32. Imamura M., Tanaka S., Hashino S., Kobayashi K., Imai K., Asaka M., Kasai M. Immunopathogenesis of GVHD. Transplant. Proc. 28:1996;1181-1183.
33. Jacob C. O., Lewis G. D., McDevitt H. O. MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: Relevance to the pathogenesis of autoimmune diseases. Immunol. Res. 10:1991;156-168.
34. Kaltschmidt C., Kaltschmidt B., Lannes-Vieira J., Kreutzberg G. W., Wekerle H., Baeuerle P. A., Gehrmann J. Transcription factor NF-κB is activated in microglia during autoimmune encephalomyelitis. J. Neuroimmunol. 55:1994;99-106.
35. Khaled A. R., Soares L. S., Butfiloski E. J., Stekman I., Sobel E. S., Schiffenbauer J. Inhibition of the p50 (NFκB1) subunit of NF-κB by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-κB expression and immunoglobulin synthesis in murine B cells. Clin. Immunol. Immunopathol. 83:1997;254-263.
36. Lentsch A. B., Shanley T. P., Sarma V., Ward P. A. In vivo suppression of NF-κB and preservation of IκB by interleukin-10 and interleukin-13. J. Clin. Invest. 100:1997;2443-2448.
37. Mackman N., Brand K., Edgington T. S. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor κB binding sites. J. Exp. Med. 174:1991;1517-1526.
38. Martinez-Tello F. J., Navas-Palacios J. J., Ricoy J. R., Gil-Martin R., Conde-Zurita J. M., Colina-Ruiz Delgado F., Cabello A., Madero-Garcia S. Pathology of a new toxic oil syndrome caused by ingestion of adulterated oil in Spain. Virchows Archiv. 397:1982;261-285.
39. Mayeno A. N., Benson L. M., Naylor S., Colberg-Beers M., Puchalski J. T., Gleich G. J. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: A chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome. Chem. Res. Toxicol. 8:1995;911-916.
40. Noriega A. R. Toxic epidemic syndrome, Spain, 1981. Lancet. 2:1982;697-702.
41. Pestana A., Munoz E. Anilides and the Spanish toxic oil syndrome (news). Nature. 298:1982;608.
42. Posada de la Paz M., Philen R. M., Borda I. A., Sicila Socias J. M., Gómez de la Cámara A., Kilbourne E. M. Toxic oil syndrome: Traceback of the toxic oil and evidence for a point source epidemic. Food Chem. Toxicol. 34:1996;251-257.
43. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Knuechel R., Baeuerle P. A., Schölmerich J., Gross V. Nuclear factor NF-κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterol. 115:1998;357-369.
44. Romano M. F., Lamberti A., Petrella A., Bisogni R., Tassone P., Formisano S., Venuta S., Turco M. C. Il-10 inhibits nuclear factor κB/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. J. Immunol. 156:1996;2119-2123.
45. Rubin R. L. Autoimmune reactions induced by procainamide and hydralazine. Kammüller M. E., Bloksma N., Seinen W. Autoimmunity and Toxicology. Immune Disregulation by Drugs and Chemicals. 1989;117-166 Elsevier Press, New York.
46. Silver R. M., Heyes M. P., Maize J. C., Quearry B., Vionnet-Fuasset M., Sternberg E. M. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N. Engl. J. Med. 322:1990;874-881.
47. Takahashi S., Fossati L., Iwamoto M., Merino R., Motta R., Kobayakawa T., Izui S. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J. Clin. Invest. 97:1996;1597-1604.
48. Thanos D., Maniatis T. NF-κB: A lesson in family values. Cell. 80:1995;529-532.
49. Traenckner E. B.-M., Wilk S., Baeuerle P. A. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκB-α that is still bound to NF-κB. EMBO J. 13:1994;5433-5441.
50. Vicario J. L., Serrano-Rios M., San-Andres F., Arnaiz-Villena A. HLA-DR3, DR4 increase in chronic stage of Spanish oil disease (letter). Lancet. 1:1982;276.
51. Whiteside S. T., Israel A. IκB proteins: Structure, function and regulation. Sem. Cancer Biol. 8:1997;75-82.
52. Whiteside S. T., Epinat J.-C., Rice N. R., Israel A. I kappa B epsilon, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J. 16:1997;1413-1426.